Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074613 | 0.88 | NPC1 (0.40) | — | |
| SCHEMBL10102066 | 0.81 | PTPN1 (0.41) | MAPTKMT2ATSHR | |
| SCHEMBL10102173 | 0.81 | MAPT (0.43) | MAPTKMT2A | |
| SCHEMBL12108726 | 0.75 | PTPN1 (0.39) | MAPTMAPK1KMT2AALDH1A1GAA | |
| SCHEMBL9286180 | 0.74 | HRH3 (0.39) | KMT2AALDH1A1 | |
| SCHEMBL10101766 | 0.74 | PTPN1 (0.43) | MAPTKMT2ATSHR | |
| SCHEMBL12108773 | 0.73 | PTPN1 (0.38) | USP2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL20370139 | 0.73 | PTPN1 (0.45) | MAPK1KMT2A | |
| SCHEMBL10102086 | 0.73 | PTPN1 (0.43) | MAPTKMT2AGAA | |
| SCHEMBL9279822 | 0.72 | PTPN1 (0.44) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | HRH4 3688/4885SMO 978/4885USP2 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.